- The disease
- Acute ischaemic stroke occurs when a blood clot blocks an artery supplying the brain, cutting off oxygen to brain tissue. It is a leading cause of death and long-term disability worldwide. Time from symptom onset to treatment is critical, as brain cells begin to die rapidly once blood flow is interrupted. Current standard-of-care treatments aim to restore blood flow, but many patients still experience significant neurological damage.
- What the asset is trying to do
- ARG-007, also referred to by Argenica Therapeutics as Xaranetide, is a peptide therapeutic being investigated for use in acute ischaemic stroke (per ASX announcements, June 2026). The specific molecular target of ARG-007 is not disclosed in the available data. As a peptide, it is a short chain of amino acids designed to interact with biological pathways involved in stroke-related brain injury; further mechanistic detail is .
- What the trial is measuring, and why it matters
- The completed Phase 2 trial (ACTRN12621000385922, known as SEANCON) investigated ARG-007 in patients with acute ischaemic stroke. Specific primary and secondary endpoints for this trial are from the available registry data. Stroke trials commonly assess endpoints such as neurological function scores, disability outcomes, and safety measures, but the precise endpoints used in SEANCON require confirmation from the trial registry or published results.
- Efficacy benchmarks in this setting
- In acute ischaemic stroke, the approved thrombolytic alteplase (tissue plasminogen activator) has been shown to improve functional outcomes when administered within 4.5 hours of symptom onset, with a rate of favourable functional outcome (modified Rankin Scale 0-1) of approximately in pivotal trials (per ). Endovascular thrombectomy, where eligible, has demonstrated rates of functional independence (modified Rankin Scale 0-2) of in major randomised trials (per ). ARG-007's Phase 2 data, if reported, are from an early-stage trial not designed or powered for direct statistical comparison with these approved therapies.
- Commercial context
- No neuroprotective agent has received regulatory approval for acute ischaemic stroke; approved treatments are limited to reperfusion strategies such as thrombolysis and mechanical thrombectomy. Argenica Therapeutics announced in June 2026 that ARG-007 (Xaranetide) completed all three assays requested by the US Food and Drug Administration (FDA) as part of an Investigational New Drug (IND) application process (per ASX announcement, 10 June 2026). The company also received a Paediatric Waiver from the European Medicines Agency (EMA) in February 2026 (per ASX announcement, 1 February 2026). A Clinical Advisory Committee was established in May 2026 to advance a Phase 2b programme (per ASX announcement, 13 May 2026). ARG-007 appears to be Argenica Therapeutics' lead pipeline asset; no partnership or licensing deal terms have been disclosed in the available data.